Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSE MELENDEZ

NPI
1134305253
CMS profile
1304870
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,812.46

140 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,673.42 139
Travel and Lodging $139.04 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSE MELENDEZ

NPI 1134305253 · CMS profile ID 1304870

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134305253?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSE MELENDEZ, NPI 1134305253, CMS profile ID 1304870. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134305253?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JOSE MELENDEZ, NPI 1134305253, CMS profile ID 1304870. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134305253?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JOSE MELENDEZ, NPI 1134305253, CMS profile ID 1304870, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1134305253?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

140 matching records · $3,812.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 140 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–140 of 140.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Philips North America LLC $16.8303/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232599100 CMS
AstraZeneca Pharmaceuticals LP $21.9603/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1215339494 CMS
Actelion Pharmaceuticals US, Inc. $29.6003/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174302351 CMS
AstraZeneca Pharmaceuticals LP $20.4003/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214804607 CMS
Philips North America LLC $13.7403/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232599104 CMS
GENZYME CORPORATION $15.9903/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233469397 CMS
GlaxoSmithKline, LLC. $16.8003/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191827239 CMS
Inspire Medical Systems, Inc. $15.5903/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251489604 CMS
Regeneron Healthcare Solutions, Inc. $21.8503/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212988903 CMS
Philips North America LLC $18.8002/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232599086 CMS
Philips North America LLC $18.4502/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232599088 CMS
Regeneron Healthcare Solutions, Inc. $27.7302/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212988901 CMS
Inspire Medical Systems, Inc. $9.9102/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251489602 CMS
Inspire Medical Systems, Inc. $3.0002/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251489600 CMS
GlaxoSmithKline, LLC. $13.6902/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190856390 CMS
Verona Pharma, Inc. $25.8402/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233767921 CMS
Actelion Pharmaceuticals US, Inc. $31.0402/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174302631 CMS
Actelion Pharmaceuticals US, Inc. $1.6002/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174302650 CMS
Inspire Medical Systems, Inc. $19.9702/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251489598 CMS
GENZYME CORPORATION $27.1102/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233469379 CMS
Viatris Specialty LLC $29.3302/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238511029 CMS
Philips North America LLC $18.6702/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232599070 CMS
Shionogi Inc $16.5802/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250714638 CMS
AstraZeneca Pharmaceuticals LP $18.5402/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214774944 CMS
GlaxoSmithKline, LLC. $11.9902/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190995804 CMS
Philips North America LLC $16.6201/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232599072 CMS
Philips North America LLC $17.6101/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232599074 CMS
Inspire Medical Systems, Inc. $13.6401/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251489596 CMS
AstraZeneca Pharmaceuticals LP $70.3201/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1215334526 CMS
Inspire Medical Systems, Inc. $10.1301/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251489594 CMS
Philips North America LLC $15.9001/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232599052 CMS
GlaxoSmithKline, LLC. $20.6001/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190359116 CMS
Actelion Pharmaceuticals US, Inc. $1.6601/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174302250 CMS
Actelion Pharmaceuticals US, Inc. $31.8101/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174303194 CMS
AstraZeneca Pharmaceuticals LP $26.2001/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1215350067 CMS
Philips North America LLC $15.6301/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232599050 CMS
Inspire Medical Systems, Inc. $14.8201/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251489592 CMS
GlaxoSmithKline, LLC. $30.9501/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190756426 CMS
Viatris Specialty LLC $31.3201/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238491799 CMS
Philips North America LLC $17.0001/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232599054 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,904.96 81
PY2020 $2,474.18 25
PY2021 $979.94 59
PY2022 $2,720.09 139
PY2023 $2,385.04 130
PY2024 $4,141.52 140
PY2025 $3,812.46 140

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $248,342.47 21
PY2024 Principal investigator $105,961.12 15
PY2023 Principal investigator $14,850.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Verona Pharma, Inc. $29,766.81 12/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891761
Principal investigator 1 Verona Pharma, Inc. $15,159.14 12/17/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891759
Principal investigator 1 Verona Pharma, Inc. $7,626.82 11/14/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891757
Principal investigator 1 Verona Pharma, Inc. $1,120.00 11/12/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891779
Principal investigator 1 Verona Pharma, Inc. $6,090.00 11/12/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891781
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,000.00 11/07/2025 Non-covered Recipient Entity
ACE CLINICAL RESEARCH GROUP
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185540733
Principal investigator 1 Verona Pharma, Inc. $16,500.00 09/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891679
Principal investigator 1 Verona Pharma, Inc. $1,852.00 09/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891681
Principal investigator 1 PFIZER INC. $2,181.60 09/07/2025 Non-covered Recipient Entity
GREATER HEIGHTS MEMORIAL PULMONARY
AN INTERVENTIONAL PHASE 23 RANDOMIZED DOUBLEBLIND THIRD PARTYUNBLINDED PLACEBOCONTROLLED PARALLELGROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH MODERATETOSEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD No dispute reported 06/30/2026 1228823719
Principal investigator 1 PFIZER INC. $143.30 08/29/2025 Non-covered Recipient Entity
GREATER HEIGHTS MEMORIAL PULMONARY
AN INTERVENTIONAL PHASE 23 RANDOMIZED DOUBLEBLIND THIRD PARTYUNBLINDED PLACEBOCONTROLLED PARALLELGROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH MODERATETOSEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD No dispute reported 06/30/2026 1228815073
Principal investigator 1 PFIZER INC. $20,950.00 08/02/2025 Non-covered Recipient Entity
Horizon Clinical Research Group
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228843564
Principal investigator 1 PFIZER INC. $275.00 05/10/2025 Non-covered Recipient Entity
GREATER HEIGHTS MEMORIAL
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228856409
Principal investigator 1 PFIZER INC. $1,245.00 05/10/2025 Non-covered Recipient Entity
GREATER HEIGHTS MEMORIAL
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228856416
Principal investigator 1 PFIZER INC. $139.95 04/24/2025 Non-covered Recipient Entity
GREATER HEIGHTS MEMORIAL
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228856422
Principal investigator 1 Genentech, Inc. $135.00 03/05/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211613418
Principal investigator 1 Genentech, Inc. $5,000.00 02/12/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211613413
Principal investigator 1 Genentech, Inc. $5,737.00 01/24/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211613421
Principal investigator 1 Genentech, Inc. $3,100.00 01/22/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211613406
Principal investigator 1 Genentech, Inc. $7,000.00 01/22/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211613410
Principal investigator 1 Genentech, Inc. $3,750.00 01/22/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211613425
Principal investigator 1 AstraZeneca Pharmaceuticals LP $101,570.85 01/17/2025 Non-covered Recipient Entity
ACE CLINICAL RESEARCH GROUP
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) No dispute reported 06/30/2026 1185540735